Review article · 2020 · Open access
Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
Journal of Personalized Medicine, 10(3), 85 · Published 12 August 2020 · DOI 10.3390/jpm10030085
In brief
“Current Biomarkers for Alzheimer’s Disease: From CSF to Blood” is a 2020 review article by Kun Zou and 2 co-authors, published in Journal of Personalized Medicine. OpenAlex counts 95 citations as of 19 November 2026, which puts it in the top 7% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Personalized Medicine.
- Citations
- 95
- Most cited in
- 2024 (26)
- Field-weighted impact
- 1.23
- References
- 92
- Authors
- 3
Abstract
Alzheimer's disease (AD) is the most common cause of dementia and affects a large portion of the elderly population worldwide. Currently, a diagnosis of AD depends on the clinical symptoms of dementia, magnetic resonance imaging to determine brain volume, and positron emission tomography imaging to detect brain amyloid or tau deposition. The best characterized biological fluid markers for AD are decreased levels of amyloid β-protein (Aβ) 42 and increased levels of phosphorylated tau and total tau in cerebrospinal fluid (CSF). However, less invasive and easily detectable biomarkers for the diagnosis of AD, especially at the early stage, are still under development. Here, we provide an overview of various biomarkers identified in CSF and blood for the diagnostics of AD over the last 25 years. CSF biomarkers that reflect the three hallmarks of AD, amyloid deposition, neurofibrillary tangles, and neurodegeneration, are well established. Based on the need to start treatment in asymptomatic people with AD and to screen for AD risk in large numbers of young, healthy individuals, the development of biomarkers for AD is shifting from CSF to blood. Elements of the core pathogenesis of AD in blood, including Aβ42, tau proteins, plasma proteins, or lipids have shown their usefulness and capabilities in AD diagnosis. We also highlight some novel identified blood biomarkers (including Aβ42/Aβ43, p-tau 181, Aβ42/APP669-711, structure of Aβ in blood, and flotillin) for AD.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zou, K., Abdullah, M., & Michikawa, M. (2020). Current Biomarkers for Alzheimer’s Disease: From CSF to Blood. Journal of Personalized Medicine, 10(3), 85. https://doi.org/10.3390/jpm10030085
MLA 9
Zou, Kun, et al. “Current Biomarkers for Alzheimer’s Disease: From CSF to Blood.” Journal of Personalized Medicine, vol. 10, no. 3, 2020, p. 85. https://doi.org/10.3390/jpm10030085.
Chicago
Zou, Kun, Mohammad Abdullah, and Makoto Michikawa. 2020. “Current Biomarkers for Alzheimer’s Disease: From CSF to Blood.” Journal of Personalized Medicine 10 (3): 85. https://doi.org/10.3390/jpm10030085.
Harvard
Zou, K., Abdullah, M. and Michikawa, M. (2020) ‘Current Biomarkers for Alzheimer’s Disease: From CSF to Blood’, Journal of Personalized Medicine, 10(3), p. 85. doi:10.3390/jpm10030085.
IEEE
K. Zou, M. Abdullah, and M. Michikawa, “Current Biomarkers for Alzheimer’s Disease: From CSF to Blood,” Journal of Personalized Medicine, vol. 10, no. 3, p. 85, 2020, doi: 10.3390/jpm10030085.
BibTeX
@article{zou2020current,
title = {{Current Biomarkers for Alzheimer’s Disease: From CSF to Blood}},
author = {Zou, Kun and Abdullah, Mohammad and Michikawa, Makoto},
journal = {Journal of Personalized Medicine},
year = {2020},
volume = {10},
number = {3},
pages = {85},
doi = {10.3390/jpm10030085},
url = {https://doi.org/10.3390/jpm10030085}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 2 | |
| 2021 | 12 | |
| 2022 | 12 | |
| 2023 | 19 | |
| 2024 | 26 | |
| 2025 | 13 | |
| 2026 | 11 |
Its field-weighted citation impact is 1.23: it has been cited 1.23 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- biomarkers
- cerebrospinal fluid biomarkers
- blood biomarkers
- amyloid-beta 42
- phosphorylated tau
- total tau
- amyloid deposition
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Zou, K., Abdullah, M., & Michikawa, M. (2020). Current Biomarkers for Alzheimer’s Disease: From CSF to Blood. Journal of Personalized Medicine, 10(3), 85. https://doi.org/10.3390/jpm10030085
How many times has this paper been cited?
95 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Personalized Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Kun Zou, Mohammad Abdullah, Makoto Michikawa.
What is the DOI of this paper?
10.3390/jpm10030085, permanently at https://doi.org/10.3390/jpm10030085. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.